Study of ABS-201 Evaluating Single and Multiple Ascending Doses in Healthy Adults With and Without Androgenetic Alopecia
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Androgenetic Alopecia (AGA), Healthy Volunteers - Male and Female
In brief
The goal of this clinical trial is to learn if ABS-201 (a new medication) is safe and tolerable when used to improve hair growth in men and women. The trial will start with healthy volunteers and if safe, will treat participants with certain types of hair loss. The main questions it aims to answer are: What medical problems, if any, do participants experience when taking a single dose or many doses of ABS-201? How does the medication, ABS-201, compare to placebo (a look alike substance that does not contain any medication). Participants who qualify for the trial will receive either ABS-201 or a placebo, and visit the study clinic for scheduled checkups and tests for approximately 1 year.
Key facts
- Study ID
- NCT07317544
- Run by
- Absci Pty Ltd.
- People needed
- 227
- Starts
- 2025-12-03
- Expected to finish
- 2028-07-01
- Last updated by the study team
- 2026-05-22
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Momentum Darlinghurst — Sydney, New South Wales, Australia (enrolling)
- Nucleus Network Brisbane — Brisbane, Queensland, Australia (enrolling)
- Sinclair Dermatology — Melbourne, Victoria, Australia (enrolling)
- Nucleus Network — Melbourne, Victoria, Australia (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.